What is the Market's View on Jazz Pharmaceuticals PLC (JAZZ) Stock's Price and Volume Trends Tuesday?

Overall market sentiment has been neutral on Jazz Pharmaceuticals PLC (JAZZ) stock lately. JAZZ receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Jazz Pharmaceuticals PLC has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on JAZZ!

See Full JAZZ Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With JAZZ Stock Today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $124.70 as of 12:56 PM on Tuesday, Dec 7, a rise of $3.19, or 2.63% from the previous closing price of $121.51. The stock has traded between $122.05 and $125.20 so far today. Volume today is light. So far 207,282 shares have traded compared to average volume of 603,169 shares. To screen for more stocks like Jazz Pharmaceuticals PLC click here.

More About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer. Click Here to get the full Stock Report for Jazz Pharmaceuticals PLC stock.